期刊
FRONTIERS IN IMMUNOLOGY
卷 8, 期 -, 页码 -出版社
FRONTIERS MEDIA SA
DOI: 10.3389/fimmu.2017.00891
关键词
inflammatory bowel diseases; ulcerative colitis; Crohn's disease; vedolizumab; natalizumab; etrolizumab; gut homing; integrins
类别
资金
- Else Kroner-Stiftung
- Interdisciplinary Center for Clinical Research (IZKF)
- ELAN program of the University Erlangen-Nuremberg
- Berlin Institute of Health
- German Research Foundation (DFG)
- DFG
- Deutsche Krebshilfe
- Deutsche Forschungsgemeinschaft
- Friedrich-Alexander-Universitat Erlangen-Nurnberg (FAU) within Open Access Publishing
The number of biologicals for the therapy of immunologically mediated diseases is constantly growing. In contrast to other agents that were previously introduced in rheumatologic or dermatologic diseases and only later adopted for the treatment of inflammatory bowel diseases (IBDs), the field of IBD was ground breaking for the concept of anti-adhesion blockade. Anti-adhesion antibodies selectively target integrins controlling cell homing to the intestine, which leads to reduction of inflammatory infiltration to the gut in chronic intestinal inflammation. Currently, the anti-alpha 4 beta 7-antibody vedolizumab is successfully used for both Crohn's disease and ulcerative colitis worldwide. In this mini-review, we will summarize the fundamental basis of intestinal T cell homing and explain the molecular groundwork underlying current and potential future anti-adhesion therapies. Finally, we will comment on noteworthy clinical aspects of anti-adhesion therapy and give an outlook to the future of anti-integrin antibodies and inhibitors.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据